

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No.03-284-E)

**PATENT** 

In re Application of:	)
Costa et al.	)
Serial No.: 10/809,144	) Before the Examiner: Unassigned
Filed: March 25, 2004	) Group Art Unit: 1642
For: Methods of Inhibiting Tumor Cell Proliferation	) ) )

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## TRANSMITTAL LETTER

- 1. We are transmitting herewith the attached papers for the above-described patent application: <u>Information Disclosure Statement and return postcard.</u>
- 2. GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES: Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.
- 3. CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 11, 2006.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Dated: May 11, 2006

Jason J. Derry

Reg. No. 50,692

	OIPE 40
	MAY 1 5 2006
/3	TOTA HANDENSTO

Sir:

4

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No.03-284-E)

	PATENT
In re Application of:	)
Costa et al.	)
Serial No.: 10/809,144	) Before the Examiner: Unassigned
Filed: March 25, 2004	) Group Art Unit: 1642
For: Methods of Inhibiting Tumor Cell Proliferation	) )
Commissioner for Patents	
P.O. Box 1450	
Alexandria, VA 22313-1450	

### INFORMATION DISCLOSURE STATEMENT

This statement is filed under 37 C.F.R. §§ 1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, Applicants hereby authorize the Commissioner to charge the fee to Deposit Account No. 13-2490.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Dated: May 11, 2006

By:

Jason J. Derr

Reg. No. 50,692

#### form 1449A/PTO Complete if Known Application No. 10/809,144 FORMATION DISCLOSURE Filing Date: March 25, 2004 **First Named Inventor** Costa et al. ATEMENT BY APPLICANT Group Art Unit 1642 (use as many sheets as necessary) **Examiner Name** Sheet 1 Attorney Docket No. 03-284-E

	U.S. PATENT DOCUMENTS							
	Cite	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines		
	No.	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Figures Appear		
		US	A1	Walling et al.	10-24-2002			
		2002/0156023						
		US	A1	O'Hare et al.	10-24-2002			
		2002/0155988	i					
		us	A1	DEPINHO	12-19-2002			
		2002/0193325	'					
		6,172,194	B1	Sherr et al.	01-09-2001	-		

				FORE	GN PATENT DOCUMEN	TS		
Examiner	Cite	te Foreign Patent Document				Date of Publication of	Pages, Columns, Lines	
Initials*	No. 1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Figures Appear	T <sup>6</sup>
		wo	01/60374	A1	Centre National De La	08-23-2001		
					Recherche Scientifique		_	l
		wo	02/083140	A1	Merck & Co., Inc.	10-24-2002		
		wo	02/26236	A1	Virginia Commonwealth Univ.	04-04-2002		
		wo	02/092013	А3	Board of Trustees of the U of I	11-21-2002		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

Substitute for form 1449A/PTO			Complete if Known		
				Application No.	10/809,144
	INFORMATION DIS	CLOS	Filing Date:	March 25, 2004	
STATEMENT BY APPLICANT			First Named Inventor	Costa et al.	
				Group Art Unit	1642
(use as many sheets as necessary)			Examiner Name		
Sheet	2	of	32	Attorney Docket No.	03-284-E

		OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		WANG et al. "Increased Hepatic Forkhead Box M1B (FoxM1B) Levels in Old-aged Mice Stimulated Liver Regarneration through Diminished p27 <sup>Kip1</sup> " Journal of Biological Chemistry 277(46) 44310-16 (November 15 2002).	
		MAJOR et al., "Forkhead Box M1B Transccriptional Activity Requires Binding of Cdk-Cyclin Complexes for Phosphorylation-Dependent Recruitment of p300/CBP Coactivators" <i>Molecular and Cellular Biology</i> 24(7)2649-61 (April 2004).	
		KRUPCZAK-HOLLIS <i>et al.</i> , "Growth Hormone Stimulates Proliferation of Old-Aged Regenerating Liver Through Forkhead Box m1b" <i>Hepatology</i> 38(6) 1552-62 (December 2003).	
-		WANG et al., "The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration" PNAS 99(26) 16881-6 (December 24, 2002).	
		KORVER et al., "The Human TRIDENT/HFG-11/FKHL 16 Gene: Structure, Localization, and Promoter Characterization" <i>Genomics</i> 46:435-442 (1997).	
		KORVER et al., "The winged-helix transcription factor Trident is expressed in cycling cells" Nucleic Acids Research 25(9)1715-19 (1997).	
		YAO et al., "Molecular Analysis of a Novel Winged Helix Protein, WIN" The Journal of Biological Chemistry 272(32) 19827-36 (August 8, 1997).	
		YE et al., "Hepatocyte Nuclear Factor 3/fork head Homolog 11 Is Expressed in Proliferating Epithelial and Mesechymal Cells of Embryonic and Adult Tissues" Molecular and Cellular Biology 17(3)1626-41 (1997).	: :
		YE et al., "Premature Expression of the Winged Helix Transcription Factor HFH-11B in Regenerating Mouse Liver Accelerates Hepatocyte Entry into S. Phase" Molecular and Cellular Biology 19(13)8570-80 (1999).	
		SUPRIATNO et al. "Overexpression of p27 <sup>Kip1</sup> induces growth arrest and apoptosis in an oral cancer cell line" <i>Oral Oncology</i> 38(7)730-736 (2002).	
		THE et al., "FOXM1 is a Downstream Target of Gli1 in Basal Cell Carcinomas1" Cancer Research 62(16)4773-4780 (2002).	

Examiner	Date	
Signature	Considered	
	Ocholacica	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.